About Dima Kuzmin
Dima Kuzmin is a director at Cloverleaf Bio.
Experience
This experience comes from Dima Kuzmin's profile and from SEC filings. For roles taken from filings, the years are when the filings name Dima Kuzmin in the role, so the role may have started earlier or lasted longer.
Cloverleaf Bio, Inc. Current
Director
2026 – Present · New Haven, CT
Develops RNA-based cancer treatments for people with cancer.
UB
Undecimal Bio Current
Board Member
2026 – Present
AT
Aptadir Therapeutics Current
Board Member
2026 – Present
NT
NV Therapeutics Current
Co-founder and Chairman of the Board
2025 – Present
TR
Trogenix Current
Co-founder and Chairman of the Board
2023 – Present
HT
Hornet Therapeutics Current
Chairman of the Board
2022 – Present
YU
Yale University Current
Assistant Professor Adjunct of Medicine
2021 – Present
KF
Kauffman Fellows Current
Kauffman Fellow - Graduated
2021 – Present
RI
Ray Therapeutics, Inc. Current
Board Member
2021 – Present
CB
Code Biotherapeutics Current
Board Observer
2021 – Present
4C
4BIO Capital Current
Managing Partner
2014 – Present
AA
Araris Biotech AG
Chairman of the Board
2020 – 2025
RT
Redpin Therapeutics
Board Member
2020 – 2022
SP
SparingVision
Board Observer
2020 – 2022
UC
UCL
Research Fellow
2012 – 2017
RT
RetroSense Therapeutics
Board Member
2015
MM
Max Planck Institute for Brain Research, Frankfurt am Main
DAAD Visiting Doctoral Fellow
2007 – 2010
NC
N.N.Blokhin Russian Cancer Research Center
Undergraduate Research Assistant
2001 – 2003
Key Colleagues at Startups
The people Dima Kuzmin works with at each company, as listed on that company's latest Form D.
Cloverleaf Bio, Inc. · Form D, Sep 9, 2026
CV
Christina Vorvis
Director
CL
Cole Lewis
Executive officer
MS
Matthias Samwer
Director
AD
Austin Draycott
President and director